Effectivity of oral recombinant DNA vaccine against Streptococcus agalactiae in Nile tilapia.

Authors :: Zhu L
Yang Q
Huang L
Wang K
Wang X
Chen D
Geng Y
Huang X
Ouyang P
Lai W
Source :: Developmental and comparative immunology [Dev Comp Immunol] 2017 Dec; Vol. 77, pp. 77-87. Date of Electronic Publication: 2017 Jul 28.
Publication Year :: 2017
Abstract: The effects of oral vaccination by two immune routes (gavage and mixed fodder administration) using a recombinant DNA vaccine SL7207-pVAX1-sip against Streptococcus agalactiae were assessed. SL7207-pVAX1-sip significantly enhanced various innate immune responses of tilapia, such as total serum protein, superoxide dismutase activity, lysozyme activity, complement C3 concentration in serum, serum antibacterial activity, and interleukin 1β and tumor necrosis factor-α. Vaccinated fish had higher relative percent survival values (57% and 63% for gavage group and mix fodder administration, respectively) at 10 weeks after S. agalactiae infection. When administered mixed fodder, the DNA vaccine SL7207-pVAX1-sip against S. agalactiae may produce more effective protection. These findings can promote the application and development of DNA vaccines in aquaculture.<br /> (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Subjects :: Administration, Oral
Animals
Complement C3 metabolism
Drug Administration Routes
Fish Proteins metabolism
Immunity, Innate
Interleukin-1beta metabolism
Muramidase metabolism
Superoxide Dismutase metabolism
Tilapia microbiology
Tumor Necrosis Factor-alpha metabolism
Up-Regulation
Vaccination
Vaccines, DNA
Bacterial Vaccines immunology
Fish Diseases immunology
Streptococcal Infections immunology
Streptococcus agalactiae immunology
Tilapia immunology

Full Text Access

Tools